PL2861733T3 - Terapia metaboliczna stresu oksydacyjnego w mózgu przez ukierunkowany neuronalny katabolizm kwasu n-acetyloasparaginowego - Google Patents

Terapia metaboliczna stresu oksydacyjnego w mózgu przez ukierunkowany neuronalny katabolizm kwasu n-acetyloasparaginowego

Info

Publication number
PL2861733T3
PL2861733T3 PL13797749T PL13797749T PL2861733T3 PL 2861733 T3 PL2861733 T3 PL 2861733T3 PL 13797749 T PL13797749 T PL 13797749T PL 13797749 T PL13797749 T PL 13797749T PL 2861733 T3 PL2861733 T3 PL 2861733T3
Authority
PL
Poland
Prior art keywords
catabolism
acetyl
brain
aspartic acid
oxidative stress
Prior art date
Application number
PL13797749T
Other languages
English (en)
Inventor
Paola Leone
Jeremy Francis
Original Assignee
Rowan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rowan University filed Critical Rowan University
Publication of PL2861733T3 publication Critical patent/PL2861733T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13797749T 2012-05-30 2013-05-30 Terapia metaboliczna stresu oksydacyjnego w mózgu przez ukierunkowany neuronalny katabolizm kwasu n-acetyloasparaginowego PL2861733T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653087P 2012-05-30 2012-05-30
EP13797749.2A EP2861733B1 (en) 2012-05-30 2013-05-30 Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid
PCT/US2013/043443 WO2013181446A2 (en) 2012-05-30 2013-05-30 Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid

Publications (1)

Publication Number Publication Date
PL2861733T3 true PL2861733T3 (pl) 2021-04-19

Family

ID=49670531

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13797749T PL2861733T3 (pl) 2012-05-30 2013-05-30 Terapia metaboliczna stresu oksydacyjnego w mózgu przez ukierunkowany neuronalny katabolizm kwasu n-acetyloasparaginowego

Country Status (6)

Country Link
US (4) US9700604B2 (pl)
EP (2) EP2861733B1 (pl)
ES (1) ES2837826T3 (pl)
IL (1) IL235999A0 (pl)
PL (1) PL2861733T3 (pl)
WO (1) WO2013181446A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015491A1 (en) * 2015-07-21 2017-01-26 Thomas Jefferson University Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
EP3364997B1 (en) * 2015-10-22 2024-01-17 University of Massachusetts Aspartoacylase gene therapy in the treatment of canavan disease
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
CN110035764B (zh) * 2016-06-22 2023-08-15 希望之城 卡纳万病的治疗
JP7587275B2 (ja) * 2018-08-30 2024-11-20 ローワン・ユニバーシティ 筋萎縮性側索硬化症の治療方法または予防方法
EP4155162A1 (de) * 2021-09-22 2023-03-29 Siemens Mobility GmbH Verfahren und vorrichtung mit achszähler zum betreiben eines bahnübergangs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002796A1 (en) * 1989-08-22 1991-03-07 Hsc Research Development Corporation Cystic fibrosis gene
CA2172963C (en) * 1993-09-29 2007-09-11 Reuben Matalon Aspartoacylase gene, protein, and methods of screening for mutations associated with canavan disease
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2010071454A1 (en) * 2008-12-17 2010-06-24 Auckland Uniservices Limited Adeno-associated viral vectors and uses thereof

Also Published As

Publication number Publication date
ES2837826T3 (es) 2021-07-01
WO2013181446A2 (en) 2013-12-05
US20220305097A1 (en) 2022-09-29
EP2861733A4 (en) 2016-07-13
US9700604B2 (en) 2017-07-11
WO2013181446A3 (en) 2014-01-23
EP2861733B1 (en) 2020-10-07
EP2861733A2 (en) 2015-04-22
US20200171134A1 (en) 2020-06-04
IL235999A0 (en) 2015-01-29
EP3778887B1 (en) 2025-07-09
EP3778887A2 (en) 2021-02-17
US20130323229A1 (en) 2013-12-05
EP3778887A3 (en) 2021-04-07
US10391153B2 (en) 2019-08-27
US20180140687A1 (en) 2018-05-24
US11382961B2 (en) 2022-07-12
US12514911B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
IL266159A (en) Treatment of circadian rhythm disorders
KR102297388B9 (ko) 대사장애를 치료하기 위한 아커만시아의 용도
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
LT2897939T (lt) Benzimidazolo karboksirūgšties amido dariniai metabolinių arba širdies ir kraujagyslių ligų gydymui
IL233715A0 (en) Treatment of diseases related to the circadian rhythm
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP2925775A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
ZA201404873B (en) Enhancement of transport of therapeutic molecules across the blood brain barrier
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
EP2869833A4 (en) TREATMENT OF INFLAMMATORY SKIN DISORDERS
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
SG11201405766SA (en) Methods for increasing efficacy of cd37-based therapy
IL233141A0 (en) Combined treatment of hearing and balance disorders
IL235999A0 (en) Metabolic treatment of oxidative stress in the brain by targeted neuronal catabolic breakdown of n-acetyl-aspartic acid
IL235821A0 (en) Catheter for photodynamic medical treatment
ZA201407597B (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
HK40043513B (en) Interval therapy for the treatment of eye diseases
IL235389A0 (en) Valiprib in combination with total brain radiation therapy for the treatment of brain metastases
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201214454D0 (en) Therapeutic treatments
GB201214456D0 (en) Therapeutic treatments